Monday AM Focus – Key Update Details On Recent Nasdaq Profile (RNXT)

Amanda Greenbrier
All Posts

3/6/23 *UPDATE*

Greetings Readers,

It’s Monday and time to hit the ground running. But before we get too far ahead of ourselves, it’s time to focus our attention back on Nasdaq profile (RNXT).

Here’s why…

RNXT was able to post a new 52-week high of $5.70 last week, but more importantly, it was able to close above a key psychological support level at $5.00 Friday.

With that $5.20 session close, RNXT had its highest close in the last 52-week period.

Now this is key. If psychological support grows at the $5.00 level, RNXT could be seeing the building blocks be put into place for it to try and run down its 52-week high from last week.

And when it comes to potential support, the $5.00 level may not be the only line to watch closely this week. RNXT is still maintaining above 3 very key lines of potential support:

  • 50-Day Simple Moving Average (SMA)
  • 200-Day SMA
  • 13-Day Exponential Moving Average

Plus, big news last week: RenovoRx Reports Full Year 2022 Fi-nan-cial Results and Achievement of Important Phase III Clinical Study Milestone

Barchart keeps reporting a total of 13 triggered technicals over at their website.

Time’s ticking to get RNXT back on radar this morning.


Virtus Junxit

3/3/23 *UPDATE*

Greetings Readers,

RNXT needs to remain on high alert again today. Here’s why.

First off, from Tuesday morning’s opening, RNXT has made a short term max blitz of approximately 36% in the matter of days.

Even after pulling back from a new 52-week high of $5.70 yesterday, RNXT has held strong above 3 of the most important lines of potential support:

  • 50-Day Simple Moving Average (SMA)
  • 200-Day SMA
  • 13-Day Exponential Moving Average

Plus, the company is hot off a big announcement Thursday: RenovoRx Reports Full Year 2022 Fi-nan-cial Results and Achievement of Important Phase III Clinical Study Milestone

Furthermore, Barchart still reports 13 bullish triggered technical indicators including its “Trend Seeker” composite indicator.

These are just a few reasons why RNXT should remain high on your watch-list today. If there are any more updates, I’ll have them out quickly.


Virtus Junxit

3/2/23 *UPDATE*

Greetings Readers,

Holy heck. Did you see that?

On Wednesday, RNXT continued its recent hot streak to hit a new 52-week high of $5.31.

This could be in part due to the fact this company made this announcement: RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023

With this good news and green move, RNXT may have built strong potential support above these 3 potential support lines.

At the same time, Barchart keeps reporting 13 triggered technical indicators plus its “Trend Seeker” composite indicator.

Don’t forget. RNXT is a low float idea with fewer than 7Mn shares.

Pull up RNXT once again before today’s opening bell. Talk again shortly.


Virtus Junxit

Original Report Below

About RenovoRx, Inc. (Nasdaq: RNXT)

RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. The company’s mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors.

The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform aims to avoid the harsh side effects typical of the current standard of care, thus improving patient well-being and extension of life so more time may be enjoyed with loved ones.


RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window.

RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and its patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).

RenovoGem is currently being studied in the Phase III TIGeR-PaC trial for the treatment of LAPC.

RenovoRx’s patent portfolio for its therapy platform and product candidates includes eight issued U.S. patents, one issued European patent, and several additional patents pending in the US, EU and Asia.

RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer (cholangiocarcinoma).

RenovoRx, Inc. (Nasdaq: RNXT) Highlights & Pipeline Overview

RenovoRx, Inc. Highlights:

  • De-risked drug development and validated RenovoTAMP approach.
  • Large first indication market ($1B) and platform broadly applicable to locally advanced solid tumors.
  • Capital efficient: <$750k average monthly burn.
  • Talented and experienced Leadership Team and Board of Directors.

Upcoming Potential Company Catalysts

RNXT Pipeline Overview


Read more key details and grab sources here (Company Presentation).


3 Potential Breakout Catalysts To Know Right Now On (RNXT)

#1. This is a low float profile.

Yahoo Finance reports RNXT to have a float of roughly 6.18Mn shares.

That’s extremely low. But what does it mean?

It means that volatility can pop up at the drop of hat. It may just take a little push like positive company news to see volatility rear its head.

And when a profile has a float this low, volatility can lead to quick, explosive moves.

Take for example the morning of December 30th. That day RNXT opened at $1.84. By January 18th, this profile had hit a high of $5.00.

That’s 171% in less than 3 weeks…

Now, I’m not saying RNXT is going to make that same type of surge in March, but the potential needs to be noted.

#2. RNXT has a multitude of bullish, triggered technical indicators this second.

Wow. I mean, wow.

Barchart is reporting RNXT to have the following technical indicators as triggered as of 3:00PM EST Monday. Check them out:

Short Term Indicators

  • 20 Day Moving Average
  • 20 – 50 Day MACD Oscillator
  • 20 – 100 Day MACD Oscillator
  • 20 – 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 – 100 Day MACD Oscillator
  • 50 – 150 Day MACD Oscillator
  • 50 – 200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 – 200 Day MACD Oscillator

The website also shares its all-important “Trend Seeker” composite indicator is triggered, too.

You’ll want to keep a close eye on these this week.

#3. A $9.00 analyst target provides over 100+% potential upside.

Check out what TipRanks is reporting:


At the time of writing, that $9.00 target would present potential upside for RNXT in the 150% range.

As I mentioned above, RNXT has already hit the $5.00 market in 2023.

$9.00 may not be so far fetched when you factor in the huge company news early in 2023:

1/18/23: RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

1/5/23: RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent

Coud more positive news early this year help spark RNXT towards that $9.00 target?


Time’s ticking to get RNXT on your radar. I’ll be in touch again shortly.


Virtus Junxit

Looking for more ?

  • March 27, 2023

($HCTI) Monday AM Focus: Trifecta Gem – Low Price, Low Float, Extreme Volatility($HCTI)

Virtus Junxit Telegram Community Please join the channel and make sure notifications are enabled, so you’re the first to know when...

  • March 24, 2023

(OXBR) Keeps On With Early Green Burst (Up Approx. 20%) As A Potential Squeeze Looms

3/24/23 *11AM Update* Greetings Readers, OXBR entering squeeze territory? More on that in a second. After blitzing today’s opening bell, OXBR...

  • March 23, 2023

Here’s A Low Float Nasdaq Idea To Get On Radar Immediately (Friday AM Breakout Idea)

3/23/23 Greetings Readers, How about a quick recap? Even with a topsy-turvy Nasdaq Market over the past few weeks, we’ve been...






0.00 | 0.00%


0.00 - 0.00




9223372036854775808.00 - 0.00


Pursuant to an agreement between Virtus Junxit, LLC and a third party media buyer, Virtus Junxit has been hired for a period beginning on 2/27/2023 to publicly disseminate information about (RNXT:US) via digital communications. We have been paid ten thousand dollars USD via bank wire transfer. We own zero shares of (RNXT:US)


You understand that the information distributed is not considered buy or sell advice, and independent due diligence should be conducted and/or advice from a registered investment advisor before making investment decisions.

Our Digital Assets, Virtus Junxit LLC, VJ Newsletters, VJ SMS, Virtus Junxit Equities and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities.

Our Digital Assets may also contain company profile pages, which are indicated as such. Information about a company contained on a company profile page has been furnished by the company or third-parties. The owner/operator of Our Digital Assets has not made any independent investigation of the accuracy of any such information and no warranty of the accuracy of any such information is provided by Our Digital Assets, its owners, employees and affiliates.

No investment advice is provided or should be construed to be provided herein. Our Digital Assets and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker- dealers or registered investment advisors. Our Digital Assets may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein.

Accordingly, users of Our Digital Assets are cautioned not to place undue reliance on such forward-looking statements. Our Digital Assets undertakes no obligation to update any forward-looking statements that may be contained herein. <a href="/disclaimer/">Disclaimer continued, please read further at this link</a>.


Subscribe to
stay informed!

Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

© 2023 Virtus Junxit